Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Merck
Dow
Express Scripts
Baxter

Last Updated: October 15, 2019

DrugPatentWatch Database Preview

COMTAN Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Comtan patents expire, and what generic alternatives are available?

Comtan is a drug marketed by Orion Pharma and is included in one NDA.

The generic ingredient in COMTAN is entacapone. There are twenty drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the entacapone profile page.

Drug patent expirations by year for COMTAN
Drug Prices for COMTAN

See drug prices for COMTAN

Recent Clinical Trials for COMTAN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Xiangya Hospital of Central South UniversityEarly Phase 1
Portland VA Medical CenterPhase 0
Oregon Health and Science UniversityPhase 0

See all COMTAN clinical trials

Recent Litigation for COMTAN

Identify potential future generic entrants

District Court Litigation
Case NameDate
Orion Corporation v. Mylan Pharmaceuticals Inc.2012-04-26
ORION CORPORATION v. SUN PHARMACEUTICAL INDUSTRIES INC.2007-11-13
Orion Corporation v. Wockhardt USA Inc.2007-09-13

See all COMTAN litigation

Pharmacology for COMTAN
Synonyms for COMTAN
(2E)-2-Cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-2-propenamide
(2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide
(E)-2-cyano-3-(3,4-dihydroxy-5-nitro-phenyl)-N,N-diethyl-prop-2-enamide
(E)-2-Cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-2-propenamide
(E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylacrylamide
(E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide
(E)-2-CYANO-3-(5-(DIHYDROXYAMINO)-3,4-DIOXOCYCLOHEXA-1,5-DIENYL)-N,N-DIETHYLACRYLAMIDE
(E)-2-cyano-N,N-diethyl-3-[3-nitro-4,5-bis(oxidanyl)phenyl]prop-2-enamide
(E)-alpha-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide
(E)-Entacapone
(E)-N, N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide
(E)-N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide
116314-67-1
130929-57-6
2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-n,n-diethyl-2-propenamide
2-cyano-3-(5-dihydroxyamino-3,4-dioxo-1-cyclohexa-1,5-dienyl)-N,N-diethyl-prop-2-enamide
2-Cyano-N,N-diethyl-3-(3,4-dihydroxy-5-nitrophenyl)propenamide
2-Propenamide, 2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-, (2E)-
2-Propenamide,2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-,(2E)-
4975G9NM6T
929E576
A806167
AB0105766
AB01275450_02
AB01275450_03
AB01275450-01
AC-393
AC1NQY02
AKOS015907685
AKOS015965009
AN-5935
BC219329
BCP22049
BCP9000645
BDBM50108879
BG0523
BIDD:GT0026
BRD-K83636919-001-01-4
C07943
C14H15N3O5
CAS-130929-57-6
CCG-213064
CHEBI:4798
CHEMBL953
cis-Entacapone
COM-998
Comtan (TN)
Comtess
CS-1266
D00781
DB00494
DSSTox_CID_26439
DSSTox_GSID_46439
DSSTox_RID_81615
DTXSID5046439
Entacapona
Entacapona [INN-Spanish]
ENTACAPONE
Entacapone (JAN/USAN/INN)
Entacapone [USAN:INN]
Entacapone [USAN:USP:INN:BAN]
Entacaponum
Entacaponum [INN-Latin]
Entacom
EX-A1130
GP9755
GTPL6647
HMS2089O16
HMS3713B20
HSDB 8251
HY-14280
I14-2812
J-005902
J-008069
J90011
JRURYQJSLYLRLN-BJMVGYQFSA-N
K-4072
KB-69546
LS-123327
LS-172316
MolPort-003-847-054
N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide
NCGC00164555-01
NCGC00164555-02
NCGC00164555-03
OR 611
OR-611
RT-012475
s3147
SCHEMBL13596593
SCHEMBL34504
SCHEMBL34505
SR-05000001452
SR-05000001452-1
SR-05000001452-2
SR-05000001452-3
SW199035-2
Tox21_112184
Tox21_112184_1
UNII-4975G9NM6T
ZINC35342787

US Patents and Regulatory Information for COMTAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Orion Pharma COMTAN entacapone TABLET;ORAL 020796-001 Oct 19, 1999 AB RX Yes Yes   See Pricing   See Pricing   See Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for COMTAN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Orion Pharma COMTAN entacapone TABLET;ORAL 020796-001 Oct 19, 1999   See Pricing   See Pricing
Orion Pharma COMTAN entacapone TABLET;ORAL 020796-001 Oct 19, 1999   See Pricing   See Pricing
Orion Pharma COMTAN entacapone TABLET;ORAL 020796-001 Oct 19, 1999   See Pricing   See Pricing
Orion Pharma COMTAN entacapone TABLET;ORAL 020796-001 Oct 19, 1999   See Pricing   See Pricing
Orion Pharma COMTAN entacapone TABLET;ORAL 020796-001 Oct 19, 1999   See Pricing   See Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for COMTAN
Drugname Dosage Strength RLD Date
➤ Subscribe Tablets 200 mg ➤ Subscribe   See Pricing

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Merck
McKesson
Mallinckrodt
Medtronic
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.